ArticleTargeted oncology2026

Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine Dynamics.

Natalia A Quijano Cardé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.